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The immune system is increasingly found to be involved in the development of several chronic illnesses,
for which allopathic medicine has provided limited tools for treatment and especially prevention. In that
context, it appears worthwhile to target the immune system in order to modulate the risk of certain
chronic illnesses. Meanwhile, natural health products (NHPs) are generating renewed interest, particu-
larly in the prevention and treatment of several chronic diseases. Over 20 scientists from fields related
to immune function and NHPs were thus convened to establish the state of knowledge on these subjects
and to explore future research directions. This review summarizes the result of discussions held during
the symposium. It thus seeks to be thought provoking rather than to comprehensively cover such broad
areas of research. Notably, a brief overview of the immune system is presented, including potentially
useful targets and strategies to keep it in an equilibrated state, in order to prevent certain disorders.
The pertinence and limitations of targeting the immune system to prevent chronic diseases is also dis-
cussed. The paper then discusses the usefulness and limitations of current experimental tools available
to study the immune modulating effects of NHPs. Finally, a concise review of some of the most studied
NHPs showing promising immunomodulatory activity is given, and avenues for future research are
described.
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Introduction
This concise review presents an expanded summary of discus-
sions held during a symposium entitled ‘Maintenance of an
efficient and equilibrated immune system through the novel
use of natural health products’ and that was the object of
a recent meeting report (1). The symposium brought together
between 20 and 30 scientists in disciplines ranging from
herbalism, ethnobotany and phytochemistry, through to basic
and clinical research in fields such as immunology, cancer and
nutrition. It was held in Montreal, Canada, on September 23
and 24, 2004 under the auspices of the Lucie and Andre ´
Chagnon Foundation, Canada’s largest philanthropic organiza-
tion. Participants were asked to discuss the relationship
between the modulation of immune system functions and the
prevention of chronic diseases, and to explore natural health
products (NHPs) that may find novel and judicious use in
this context. Other symposium details, including the list of par-
ticipants, can be found in the published meeting report (1).
The complexity of the immune system is secondary only to
that of the central nervous system although the immune system
is older in evolutionary terms (2). Our immune system is often
conceptualized as possessing two principal components:innate
and adaptive immunity, which work in concert to defend the
body against infection.
The innate system is ancestral and present in invertebrates as
well as vertebrates. It is neither anticipatory (no memory) nor
clonal and does not respond to environmental changes. The
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isms through receptors for highly conserved and essential
microbial molecules, such as lipopolysaccharides present on
the cell wall of Gram-negative bacteria and lipoteichoic acids
present in Gram-positive bacteria. Indeed, the cells of the
innate immune system represent the first line of defence in
the immunosurveillance network. The primary cells involved
in the identification and spontaneous lysis of offensive targets
(virus-infected cells, tumor cells, bone marrow stem cells and
embryonic cells) are natural killer (NK) cells, which have
been the object of several ground breaking studies in the later
part of the last century (3–8). These cells originate from the
bone marrow, from which they travel in a unidirectional and
almost exclusive way to the spleen; very few NK cells are
found in lymph nodes or other secondary sites such as the
gut-associated and bronchi-associated lymphatic tissue
(3,9–15). Nonetheless, NK cells are lymphoid in morphology
and need cells of the macrophage/monocyte lineage for the
full expression of NK cell production or function. NK cells
are numerically and functionally low in youth and old age,
and maximal during the reproductive periods in mammals.
Moreover, an inverse relationship exists between the rise and
fall of NK cells and the incidence of tumor growth. This
phenomenon is believed to be more than coincidental. The
studies of Dussault and Miller (16–18) have elucidated some
of the factors underlying this relationship. In elderly mice,
bone marrow NK cell production and their capacity to bind
onto offensive target cells are significantly reduced relative
to that of the young adult mammal, thus attenuating any
potential for tumor cell lysis. In contrast, very young mammals
produce NK cells at a level comparable to that of young
adults, but there exist NK-suppressive factors in the micro-
environment of the spleen that prevent NK cells from lysing
offensive targets. In humans, this corresponds to a time when
pediatric leukemias and lymphomas are prevalent. This
demonstrates, in part, the importance of NK cells and of the
adaptive system in general for the maintenance of optimal
immune function.
In contrast, the adaptive system, also termed specific
immunity, is acquired through interactions with the environ-
ment. It is subject to induction, anticipation (immune memory)
and clonal expansion. Adaptive immune responses are central
to the body’s ability to eliminate bacterial, viral and parasitic
infections. Understanding these responses is the key to under-
standing the phenomena of allergy, autoimmunity, vaccina-
tion, cancer and organ graft rejection/acceptance. Adaptive
immunity has been known for over a century and an abundant
literature exists, which is fully reviewed in classical works
such as those of Roitt and Delves (19) and Paul (20). The cells
involved in adaptive responses are thymus (T)-derived cyto-
toxic T lymphocytes and helper T lymphocytes (the latter
existing in two subsets: Thl and Th2), bone (B) marrow-
derived lymphocytes and assorted accessory cells (dendritic
cells, macrophages and stromal cells). Lymphoid tissue is
distributed all over the body. Lymphocytes (along with
several of their accessory cells) circulate to and through the
spleen, lymph nodes, specialized lymphoid tissue in the
gut (Peyer’s Patches and appendix), bronchi and oropharynx
(adenoids and tonsils). These ‘secondary’ sites serve as clonal
generating stations for T and B lymphocytes, once the appro-
priate antigen (from bacterial, viral or parasitic sources) has
been encountered. Thus, an army of identical and antigen-
specific lymphocytes is uniquely directed at the offensive anti-
gen, ensuring its elimination in normal animals, including
humans. Cytotoxic T lymphocytes destroy virus-infected cells
by making direct contact with the latter in order to induce
cytolysis. Th1 cells, on the other hand, ‘activate’ the appropri-
ate accessory cell, and it is the latter that then delivers the
cytolytic blow. Th1 cells are the target of the AIDS virus,
and when the vital Th1 cells are crippled throughout the
body (advanced AIDS), opportunist infections ultimately kill
the infected host (human or animal). Th2 lymphocytes activate
B lymphocytes whose function is to produce an appropriate
antibody against the offensive antigen, leading to its destruc-
tion and elimination.
The innate and adaptive systems are highly integrated and
interdependent (21). In addition to being a requisite for adap-
tive immunity, the innate system is responsible for the early
killing and clearance of infectious pathogens and the resolu-
tion of the inflammatory response. The most important means
by which the immune system communicates internally and
externally is through the use of cytokines, small soluble signal-
ing molecules. Cytokines play a crucial role in the selection,
initiation and modulation of an appropriate immune response.
The signaling network of cytokines is characterized by its
complexity (synergy and antagonism) and by its redundancy
(parallelism) that ensure the speed and flexibility required for
an effective immune response.
The immune system can give rise to several disorders when
itisweakenedoroveractivated(Table 1).Forinstance,adefec-
tive adaptive immune response can lead to recurrent infection
despite previous encounters with antigens, to lowered toler-
ance to self-organs and tissues leading to organ-specific
autoimmunity, and to faulty recognition and elimination of
transformed cells leading tocancer. However, an overactivated
innate immune response can cause chronic infection because
of inefficient clearing of pathogen or chronic inflammation
due to an inefficient regulation or resolution of the inflamma-
tory response. Chronic inflammation can lead to extensive
non-specific destruction of neighboring tissue. In fact, inflam-
mation and the immune system are intimately tied. In addition,
Table 1. Health effects of imbalances of the immune system
Immune system status Attributable pathologies
Weak Prone to opportunistic infectious diseases
Prone to cancer establishment and tumor escape
Overactivated Chronic inflammation and autoimmunity
(e.g. Type 1 diabetes)
Heart disease, cancer (e.g. lymphoid)
Skin disease, allergies and asthma
Joint and tissue destruction
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development of several chronic diseases such as arterioscler-
osis, diabetes, neurodegenerative diseases and even cancer.
Immune dysfunction has also been linked to conditions
such as chronic pain, anxiety and depression, albeit
sometimes as a consequence rather than a cause, and may be
involved in other disease processes in a manner that is cur-
rently not fully understood (22). Indeed, its diverse influence
upon health may be in part due to its evolution as a defence
mechanism and in part due to its origins, possibly as a sensory
organ (23).
Is the Immune System a Good Target to
Aim at In Order to Prevent Chronic Disease?
Yes, But...
A first question to address is whether the immune system is
a good target to select in the fight to prevent chronic diseases.
Consensus is generally positive with some important reserva-
tions being brought forward. In fact, it is accepted that the
immune system represents our arsenal to combat infection
and disease. As mentioned, an underactivated immune system
increases risks of opportunistic infection and uncontrolled neo-
plastic tissue growth, while an overactivated immune system
leads to many afflictions, including inflammation, allergy
and autoimmunity. Hence, an unchecked and unbalanced
immune system hampers good health and quality of life. This
explains the consensus ‘Yes’ given as an answer by the experts
regarding the pertinence of targeting the immune system to
prevent chronic disease.
However, it must be noted that the immune system carries
out its important defensive function in intimate and coordi-
nated interaction with the nervous and endocrine systems
(24,25). The innate complexity of the immune system and of
its communication tool, the cytokines, is thus further compli-
cated by these interactions with the nervous and endocrine sys-
tems. Some concern also arises when considering that
targeting the immune system may be too reductionist an
approach, particularly when dealing with complex pathologies
like cancer. These considerations form the basis of the ‘but...’
part of the answer given in the title to this subsection.
Promising Research Avenues and Markers
It is important to consider that invertebrate species lack adap-
tive immunity but are clearly able to deal effectively with
infections. It is also interesting to note that these organisms
do not appear to develop cancer or autoimmune disease (at
least not in any readily recognizable form), but they do demon-
strate senescence (26–28). Therefore, the apparent absence of
these age-related diseases in invertebrates could support an
evolutionary argument to focus disease prevention upon main-
tenance of efficient and equilibrated innate immunity.
If this line of reasoning is correct, then the immune cells of
greatest interest are ones of the NK cell lineage described
above. These immune cells are present in invertebrate and
vertebrate species and serve as a link between innate and adap-
tive immunity in vertebrates, as mentioned (25). Indeed, NK
cell function has been identified as a reliable measure of
immunotoxicity for use in pharmaceutical safety testing (29)
and could perhaps provide a means to monitor immune system
equilibrium.
Another important point to consider relates to the problem of
markers for immune system function. It is difficult to reach
a consensus on the appropriate markers to use in order to moni-
tor the maintenance of a healthy immune system, primarily
because biological heterogeneity precludes readily identifiable
thresholds for concern in the prevention of chronic disease.
However, there exist potential novel avenues to explore,
including the use of NK cell activity, as mentioned above, or
the use of a constellation of markers, of which cytokines and
cytokine receptors would be a major part. Much has been writ-
ten about the validity and validation of biomarkers for health
monitoring (30). While it is beyond the scope of this paper to
discuss these issues at length, it is worth highlighting some
general considerations. Firstly, biomarkers must be relevant
to the question being asked and practical to use in the desired
setting since advances in analytical sensitivity can now pro-
vide detection limits at concentrations often below those that
have biological importance (31). Secondly, it is generally eas-
ier to define thresholds for intervention (i.e. when a disease
requires treatment) than for early detection or prevention (i.e.
before onset of the disease). Indeed, thresholds for disease pre-
vention require a good definition of what constitutes the ‘nor-
mal’ condition. However, biological heterogeneity and the
redundancy present within the immune system makes the
establishment of precise ‘normal ranges’ especially difficult.
Therefore, although NK cell activity and cytokine assays can
be used as reliable measures for treatment intervention
(32,33) they have yet to be shown to be practical biomarkers
for defining a threshold for the early detection of chronic
illnesses.
Finally, one interesting alternative to conventional immune
system biomarkers is the presence and quality of microparti-
cles present in the blood. Such microparticles, including exo-
somes, originate from several cells, including some
prominent immune cells, and may represent a novel type of
intercellular signaling mechanism (34,35). Hence, research
into the development of novel and pertinent biomarkers will
certainly contribute to finding ways to modulate the immune
system and prevent certain chronic diseases.
Tools to Study the Immune System and NHPs
In this section we briefly review several experimental models
and approaches that have been used to study immunomodula-
tory NHPs. Table 2 summarizes the advantages and limitations
of each modality. Human clinical studies remain the gold stan-
dard upon which scientists and health care professionals can
rely to determine the usefulness and efficacy of a given
NHP. Nonetheless, animal models, in vitro bioassays, and
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helpful in delineating the mode of action of NHPs. Finally, epi-
demiological studies bring a wealth of information on the
influence of genetic (germ line) and environmental factors on
health outcomes in the general population and pertinent
subgroups.
In addition, it is generally recognized that a great effort
should be placed on the standardization of methods used to
study immune modulation by NHPs. In terms of herbals, this
also includes a crucial component of standardization of the
herbal preparations themselves. As mentioned in Table 2
above, the greatest inconsistencies of clinical research related
to immunomodulatory NHPs are caused in major part by the
lack of quality control of the source materials used (36). The
US agency NCCAM came to a similar conclusion after its first
5 years of functioning and is now focusing on more preclinical
studies to prepare better clinical studies, notably with herbal
products (http://nccam.nih.gov/about/plans/2005/index.htm).
NHPs having Immunomodulatory Activity
During the last century, modern medicine has contributed
major advancements to sanitation and public health initiatives
and discoveries like antibiotics and vaccination. These effi-
ciently hindered the progression of infectious diseases through
the population. In fact, modern medicine has succeeded best in
treating acute illnesses. It is in the realm of chronic diseases
that modern medicine and drugs have been more disappointing
and that NHPs have elicited resurgent interest. In this section,
we review the evidence for the immunomodulatory action of
several NHPs, including probiotics, products of animal origin
(principally milk and thymic extracts), nutritional factors
(especially vitamins, minerals and fatty acids) and herbal
products. Table 3 summarizes the strongest evidence brought
forward for some of the most promising NHPs. Readers are
also oriented to recent reviews (37,38) for complementary
information.
The gastrointestinal (GI) tract and the skin epidermis are the
major barriers humans possess to confront the external envi-
ronment. Both are responsible for maintaining systemic
integrity and use lymph nodes as efficient immune check-
points. The GI tract distinguishes itself by holding the greatest
number of lymph nodes, and also by being the most intricate
and complex immune organ. Probiotics are live bacteria that
colonize the GI tract. They have received a lot of research
attention, particularly in clinical studies in children and the
elderly (39–42). Indeed, they positively affect general health
going from the development of the immune system in infants
right after birth to the enhancement of general immunity in
the elderly (critically exposed to immunosenescence). Pro-
biotics offer much promise because they appear not only to
help with the maturation of the visceral immune system but
also to equilibrate the body’s defence mechanisms. In that
sense, they act as true immunomodulating agents, enhancing
immunity when it is weakened or developing, and
buffering exaggerated reactions (e.g. allergies and inflamma-
tory bowel disease). They also represent the only NHP cate-
gory that research has shown to have well established curing
Table 2. Tools to study NHPs as related to the immune system
Experimental models/tools Pros Cons
In vitro measurement on
cell culture
Can target specific effects of the studied product on
specific cell types
Simplistic model, systemic effects not taken into
consideration
Very helpful for investigating cellular and molecular
mechanisms
NHP administration generally not physiological
Large number of very well characterized systems with
efficient markers of activation/inhibition
Genomics/proteomics New analytical tools Cost of utilization
Very precise results Availability of source material
Can be used in fundamental research as well as clinical trials
Animal models Mouse has a very well characterized genome Despite high similarities with man, uncertainty whether
mice and men react the same way
Complete living organism Difficulty in measuring environmental components
on a mouse
Genetically modifiable (transgenic and knock out mice)
Large number of well characterized models for
several human pathologies
Clinical trials Gold standard for safety and efficacy Weakness or lack of proper markers to evaluate success
of intervention
Direct and systemic effects measured on health Improper administration/standardization of NHPs
Epidemiological studies Large-scale studies on the population Challenge in scientifically measuring dietary exposure in
the population
Can include both the environmental and germ
line components of disease
Large cohorts needed for significant conclusions
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principally by
1. Improving the intestinal immunologic barrier function
through spatial exclusion of other pathogenic microbial
that could otherwise colonize the gut (43,44).
2. Restoring normal intestinal permeability (45) in the
face of inflammatory or allergic diseases by still ill-
defined mechanisms that include cell wall and DNA
components playing the role of immunomodulatory
products (46) and by lowering the production of pro-
inflammatory cytokines (47,48).
3. Synthesizing vitamins (folic acid, biotin and other group
B vitamins, vitamin K and so on) (116).
Suggestions have been made that probiotics may absorb heavy
metals (49–51) and thus help their elimination through the
feces. Probiotics may also promote the production of enzymes
that help decrease the severity of certain food intolerances/
allergies (52). However, these actions have not been fully
documented.
Data on milk peptides, bovine colostrum and thymic extracts
are less convincing in terms of immune modulation, most of
the research having been done in cellular models in vitro and
showing contradicting results (53–64). Several peptides
released from enzymatic hydrolysis of milk proteins were
reported to modulate immune functions such as phagocytosis,
lymphocyte proliferation and cytokine production. The type
of enzymatic treatment has an influence on the immunomodu-
latory functions of peptides generated from milk proteins and,
without standardized procedures, it is difficult to drawn con-
clusions from those studies. Further research, especially clini-
cal trials, will be required to identify the impact of those
products on the immune system in humans.
However, stronger evidence was presented to support the
usefulness of a number of micronutrients to prevent certain
chronic illnesses. A new term coined ‘nutraprevention’ is
applied to the use of empirical combinations of foods, spices
and other food-grade herbals in the fight against cancer (65).
So far, this approach is based on epidemiological studies
clearly showing relationships between cancer prevalence and
food consumption in different populations around the world.
Moreover, research is now showing potent antiangiogenic
activity for polyphenolic components of green tea (66–68);
angiogenesis being the process by which growing tumors pro-
mote the development of new blood vessels to ensure their sur-
vival. Several plant constituents, including soy isoflavones
(69,70) and compounds in cruciferous vegetables (71,72), are
also known to modulate enzymes involved in xenobiotic bio-
transformation, namely, the activation or detoxification of
‘foreign’, pro-carcinogenic chemicals. Vitamin C has been
clearly linked to the modulation of immune function, particu-
larly in the context of novel research showing improved cogni-
tive status in patients with neurodegenerative disorders (73),
which are increasingly shown to involve an immune dysfunc-
tion component. Similarly, polyunsaturated fatty acids, in par-
ticular the now famous w-3 fatty acids, have been used
successfully in the management and prevention of several
inflammatory and allergic diseases (74–76). However, clinical
research on lipids has yielded inconsistent results concerning
their potential to modulate immune system function. This state
of affairs is related to poor study design and to the great vari-
ability in immune cells selected and methods used to assess
immune function.
Intake of green tea, Brassica vegetables (e.g. broccoli, cab-
bage and others) and soy foods has been shown to be associ-
ated with lower risk of several cancers in epidemiologic
studies [reviewed in (77–82)]. Furthermore, data from experi-
mental studies suggest that green tea and its constituents, such
as isoflavones, may modulate markers of inflammation and
immune function (83–87). A limited number of herbal prod-
ucts also show promise in the realm of immune modulation.
Table 3. Promising NHPs exhibiting modulatory effects on the immune system
NHP source Prevention Treatment
Probiotics Helps immune system maturation (96) Helps manage atopic eczema/dermatitis (97)
Helps prevent allergies (96), atopic disease and
hypersensitivities in infants (98,99)
Promise in treating inflammatory bowel disease (IBD)
through immune modulation (100,101)
Enhances immunity in the elderly (102,96)
Green Tea (EGCG, flavonoids ...) Daily intake could prevent tumor
growth (65,103,104)
Potent antiangiogenic effect (66–68)
Potent anti-inflammatory effect (105,106)
Vitamins C and E, n-3 fatty acids Antioxidant: decrease oxidative stress in several
chronic diseases (73)
Helps manage arthritis, asthma and IBD (76,75)
Anti-inflammatory: n-3 fatty acids (74)
Echinacea Enhance antitumor immunity (mouse NK cells) (107) May help treat upper respiratory tract infection (108)
Enhance NK cell immunity in aged mice (107) Putative antifungal properties (109) and antiviral properties (110)
Ginseng (ginsenosides) Immunosuppressant properties (111) May have benefit as an adjunct to cancer therapy (112)
Anti-inflammatory properties (113)
Ginseng (polysaccharides) Immune stimulating properties (NK, macrophages
and antibody production) (114)
Helps clear infections agents like Staphylococcus aureus,
Pseudomonas aeruginosa and Candida albicans in mice (115)
eCAM 2005;2(4) 517It is notably the case with Echinacea that has received signifi-
cant scientific attention in the past two decades, particularly in
studies on upper respiratory tract infections (36,88,89). Among
its many immune modulating activities reported, activation of
macrophages has been demonstrated most convincingly. How-
ever, novel mechanisms of action include effects on B and T
lymphocytes as well as NK cells (90,91). In particular, Currier
and Miller (90) observed that upon incorporating Echinacea in
the daily diet of elderly mice for only 14 days NK cell produc-
tion in the bone marrow, as well as the number of mature func-
tional NK cells reaching the spleen, increased to levels found
in young adults (92). Brousseau and Miller (93) have also
revealed that daily dietary intake of Echinacea throughout
life, beginning in youth, increased the number of individuals
reaching old age to 74% as opposed to 46% in control animals.
Thus, any herbal treatment that would augment NK cells
would clearly be worthy of investigation for its therapeutic/
prophylactic potential, especially in the realm of immune
modulation.
Ginseng is the other herbal that shows much promise as an
immune modulating NHP. Indeed, it appears to have both
immunostimulant and immunosuppressant activities, which
would lend credence to the view that ginseng is an ‘adapto-
genic’ NHP. Immunostimulant activities have been attributed
to polysaccharide fractions, notably acting on both macro-
phages and B lymphocytes (94,95). However, ginsenosides
display immunosuppressant activity in vitro by inhibiting
cytokine release in activated macrophages (I. Lemaire, unpub-
lished results). Hence, further research is warranted on ginseng
and other adaptogenic herbals to define their potential use in
preventing chronic diseases related to immune dysfunction.
Summary and Conclusion
Dysfunction of the immune system is clearly implicated in the
development of several chronic diseases. Hence, attempting to
maintainanefficient andequilibratedimmunesystemisavalid
approach to prevent certain chronic illnesses. However, this
approach is limited by the great complexity of the immune sys-
tem and its close interactions with the nervous and endocrine
functions. This is further hampered by the difficulty in identi-
fying reliable and convenient analytical tools to assess immune
function and its modulation. In that context, interesting areas
for future research include NK cells, constellation of cytokine
markers and receptors and assessment of blood-borne
microparticles. Despite these limitations, research on NHPs
has shown that certain products offer novel avenues to modu-
late the immune system and help prevent chronic diseases.
The most promising ones are probiotics, nutraprevention
(combinations of biologically-active fruits, vegetables and
spices) and so-called adaptogenic plants (e.g. echinacea and
ginseng). Notwithstanding these encouraging results, future
research efforts with NHPs will need to address the important
issues of standardization in both product quality and research
methodology. Among areas to favor in the research agenda
on NHPs and immune modulation, this review highlights the
following needs: (i) studies on the interaction between NHPs
and immune cells, particularly the influence of NHPs on the
innate immune system; (ii) epidemiological studies and clini-
cal studies with NHPs in chronic illnesses where immune dys-
function may play a role. Finally, social/economic impact of
NHPs in health care must also be considered.
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